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N-3 polyunsaturated fatty acids (PUFAs) are thought to have pro-
tective effects against cardiovascular disease. Here, we report the
relationship between serum PUFA concentrations and plaque
composition, as evaluated by virtual histology-intravascular
ultrasound (VH-IVUS). Consecutive patients (n¼61) who under-
went percutaneous coronary intervention (PCI) were pre-
operatively examined using VH-IVUS to assess the composition
of culprit plaques. Gray-scale IVUS and VH-IVUS data of ﬁbrous,
ﬁbro-fatty, necrotic core, and dense calcium regions of plaques
were estimated at the minimal luminal area sites of culprit lesions.
Serum levels of high-sensitivity C-reactive protein (hsCRP) and
PUFAs, including eicosapentaenoic acid (EPA), docosahexaenoic
acid (DHA), and arachidonic acid (AA), were compared between
patients with (ACS, n¼27) and without acute coronary syndrome
(non-ACS, n¼34) before PCI. Multiple logistic regression analysis
of the data showed that EPA/AA under the median was more
highly associated with ACS than hsCRP over the median. In addi-
tion, EPA/AA was negatively correlated with the percentage of
ﬁbrous plaque regions and EPA/AA and DHA/AA were positively
correlated with the percentage of dense calcium regions in pla-
ques. Furthermore, the correlation index of EPA/AA was the mostvier Inc. This is an open access article under the CC BY license
ax: þ81 245 34 5205.
p (T. Ohwada).
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T. Ohwada et al. / Data in Brief 7 (2016) 1237–12471238highly (R¼0.513) correlated with the percentage of dense calcium
regions in plaques.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Cardiology, Atherosclerosis
ore speciﬁc
subject areaAcute coronary syndrome, Poly-unsaturated fatty acids (PUFAs)ype of data Tables, Figures
ow data was
acquiredProspective studyata format Raw data, Analyzed
xperimental
factorsVirtual histology intravascular ultrasound images were quantiﬁed using
echoPlaque 4.0 software (INDEC Systems, Inc.)xperimental
featuresCorrelations between VH-IVUS image data and serum PUFA levels in coronary
plaques of 61 cardiovascular patientsata source
locationFukushima, Japanata accessi-
bilityData is with this articleValue of the data
 The data provides information on the effect of PUFAs on the coronary vascular composition of
cardiovascular disease patients.
 This data is valuable for further clinical examination of PUFAs and experimental vascular models.
 The analysis of plaque composition based on the gray-scale IVUS and VH-IVUS data is expected to
be useful for assessing how PUFAs or other substances impact coronary vascular composition.
 The data may be potentially valuable to other researchers examining the relationship between
PUFAs and vascular calciﬁcation.1. Data
The serum levels of eicosapentaenoic acid (EPA), EPA/arachidonic acid (AA), docosahexaenoic acid
(DHA), and DHA/AA in acute coronary syndrome (ACS) patients were lower than those in stable
coronary disease (SCD) patients (Table 1) (Fig. 1). In addition, the vessel and plaque areas in ACS
patients were larger than those in SCD patients (Fig. 2); however, the percentage of ﬁbrous, ﬁbro-
fatty, necrotic core, and dense calcium regions at sites of minimal luminal area within culprit lesions
were comparable between the two patient groups (Table 2, Fig. 3), although the percentage of dense
calcium regions in plaques tended to be higher in SCD patients than ACS patients (Table 2, Fig. 3).
Univariate and multiple logistic regression analyses revealed that low DHA, low EPA, low DHA/AA,
and low EPA/AA were independent factors for the risk of ACS (Tables 3 and 4). The percentage of
dense calcium regions in plaques positively correlated with EPA/AA (Table 5, Fig. 5), EPA (Table 5,
Fig. 6), and DHA (Table 5, Fig. 7), and EPA/AA was also inversely correlated with %plaque burden (ratio
of plaque area to vessel area) (Table 5, Fig. 4).
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2.1. Study population
This study was approved by the Fukushima Red Cross Hospital Ethics Committee (April 24, 2012),
and written informed consent was obtained from all study subjects before enrollment. The studyTable 1
Comparisons of patient characteristics and laboratory data between ACS and SCD patients.
Characteristic ACS n¼27 (%) SCD n¼34 (%) P
Age (yrs7SD) 69714 71710 0.59511
Male sex 20 (74.1) 24 (70.6) 0.763
Clinical histories
Diabetes mellitus 18 (66.7) 20 (58.8) 0.5301
Hypertension 19 (70.4) 24 (70.6) 0.9852
Dyslipidemia 17 (63.0) 13 (38.2) 0.055
Smoking 15 (55.6) 22 (64.7) 0.4674
Previous PCI 1 (3.7) 12 (35.3) 0.0028*
Previous CABG 0 (0) 1 (2.9) 0.3689
Hemodialysis 1 (3.7) 0 (0) 0.2579
Oral medications
CCB 8 (29.6) 14 (41.2) 0.3509
ACEI/ARB 8 (29.6) 17 (50) 0.1081
Beta-blocker 3 (11.1) 1 (2.9) 0.2004
Diuretics 3 (11.1) 2 (5.9) 0.4596
Antiplatelet drugs 2 (7.4) 20 (58.8) 0.000033*
Statin 5 (18.5) 16 (47.1) 0.0198*
DT for DM 7 (25.9) 12 (35.3) 0.4326
Culprit vessel
RCA 12 (44.4) 11 (32.4) 0.3785
LAD 13 (48.1) 17 (50.0) 0.8857
LCX 2 (7.4) 6 (17.6) 0.4266
Laboratory data
TC (mg/dl) 203.1746.6 181.4730.1 0.0514
TG (mg/dl) 150.3779.7 160.87103.6 0.75
HDL-C (mg/dl) 51.6716.2 50.6712.3 0.8447
LDL-C (mg/dl) 131.8742.3 111.4727.5 0.1137
Creatinine (mg/dl) 1.270.9 0.970.3 0.1488
Uric acid (mg/dl) 6.071.8 5.471.3 0.1834
Na (mEq/l) 139.073.3 141.672.0 0.0036*
K (mEq/l) 4.270.4 4.370.4 0.6478
CL (mEq/l) 102.273.7 106.072.5 0.0003*
HbA1c 6.270.8 6.471.1 0.5434
WBC (103/μl) 9.473.2 6.372.0 0.0006*
Hb (g/dl) 12.973.0 13.672.2 0.3977
Plt (103/μl) 204777.4 202.4743.6 0.9235
hsCRP (ng/ml) 35410761327 195873818 0.0088*
DGLA (μg/ml) 34.5712.3 37.8712.2 0.2962
AA (μg/ml) 173.4748.7 174.4745.5 0.9306
EPA (μg/ml) 49.5728.3 92.9742.1 0.00001*
DHA (μg/ml) 121.8737.7 157.2738.6 0.0007*
EPA/AA 0.29770.143 0.56870.306 0.00005*
DHA/AA 0.73270.225 0.94570.290 0.0027*
Values are the mean7SD or number of patients or (percentage). *:The difference between ACS and SCD is statistically sig-
niﬁcant with Po0.05. AA, arachidonic acid; ACEI/ARB, angiotensin-converting enzyme inhibitor and angiotensin II receptor
blocker; ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; CCB, Calcium-channel blockers; DGLA, dihomo-
gamma-linolenic acid; DHA, docosahexaenoic acid; DT for DM, drug therapy for diabetes mellitus; EPA, eicosapentaenoic acid;
HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LAD, left anterior descending coronary
artery; LCX, left circumﬂex coronary artery; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary inter-
vention; Plt, platelet; PUFA, polyunsaturated fatty acids; RCA, right coronary artery; SCD, stable coronary disease; TC, Total
cholesterol; TG, Triglyceride; WBC, white blood cell.
T. Ohwada et al. / Data in Brief 7 (2016) 1237–12471240population consisted of 27 ACS patients, which included those with unstable angina (n¼6) and acute
myocardial infarction (AMI, n¼21) and 34 SCD patients, which included those with stable effort
angina pectoris (EAP, n¼29) and silent ischemia (n¼5). The diagnostic and exclusion criteria are
described elsewhere [1–3]. The clinical histories of patients are listed in Table 1.2.2. IVUS image acquisition and analysis
Intravascular ultrasound was used to examine culprit lesions. A phased-array, 20-MHz, 3.2-F IVUS
catheter (Eagle Eye, Volcano Corp., Rancho Cordova, CA) was placed into the distal coronary artery
and pulled back to the aorto-ostial junction using a motorized catheter pull-back system set at
0.5 mm/s (Eagle Eye, Volcano Corp.). The gray-scale IVUS and captured radiofrequency (VH-IVUS)
data were analyzed using echoPlaque 4.0 software (INDEC Systems, Inc., City, State). Corresponding
images of IVUS examinations were identiﬁed at culprit lesions between segments. The gray-scale
IVUS and VH-IVUS images were analyzed at sites of minimal luminal area within culprit lesions, as
previously described [4]. Gray-scale IVUS analysis was performed according to the American College
of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and
Reporting of Intravascular Ultrasound Studies [5]. In the conventional gray-scale IVUS analysis, cross-
sectional images were quantiﬁed for luminal diameter, vessel diameter, intima diameter, luminal area,
vessel area and plaque area. Plaque burden was calculated as the ratio of plaque area to vessel area.
The remodeling index was calculated as the ratio of vessel area at the site of the measured lesion
(sites of minimal luminal area) to the reference vessel area (average of the proximal and distal
reference segments). The four VH-IVUS plaque components were color-coded as follows: dark green
(ﬁbrous), light green (ﬁbro fatty), red (necrotic core), and white (dense calcium), and are reported as
the area or percentage of plaque area. Representative images of lesions from ACS (low EPA/AA ratio;
0.29) and SCD patients (high EPA/AA ratio; 0.82) are shown in Fig. 1. The intraobserver (r¼0.98, 0.98
and 0.99) and interobserver (r¼0.96, 0.97, and 0.98) variability for the measurements were deter-
mined to be acceptable (Table 2).2.3. Laboratory analyses
Blood examinations for lipid levels were performed within 2 days prior to PCI. Fasting blood
samples were collected and after centrifugation and prompt freezing at 80 °C, serum samples were
shipped to SRL, Inc. (Tokyo, Japan) for the measurement of dihomo-gamma-linolenic acid (DGLA),
EPA, DHA, and AA levels using a gas chromatography method [6]. Plasma concentrations of hsCRP
were quantiﬁed using the nephelometry method [7].Fig. 1. Representative VH-IVUS images of lesions with low (0.29; left panel) and high EPA/AA (0.82) ratios (right panel). Both
images indicate dark green (ﬁbrous), light green (ﬁbro-fatty), red (necrotic core), and white (dense calcium). The low EPA/AA
lesion (left panel) was predominantly ﬁbrous (dark green, 66.89%) and contained few regions of dense calcium (white, 0.37%).
In contrast, the high EPA/AA lesion (right panel) contained a high proportion of dense calcium regions (white, 22.76%).
Fig. 2. Comparisons of gray scale IVUS data between ACS and SCD patients. Lumina area, vessel area and plaque area are
presented as area (mm2), and plaque burden is presented as percentage (%). N.S: not signiﬁcant, *Po0.05.
Table 2
Comparisons of gray scale-IVUS and VH-IVUS data between ACS and SCD patients.
ACS (n¼27) SCD (n¼34) P
Gray scale-IVUS data
Max luminal diameter (mm) 2.07870.778 1.95270.281 0.4368
Min luminal diameter (mm) 1.63570.195 1.61070.173 0.6172
Average luminal diameter (mm) 1.77670.239 1.76270.183 0.8131
Luminal area (mm2) 2.53170.695 2.47770.526 0.7398
Max vessel diameter (mm) 4.67270.907 4.24770.760 0.0573
Min vessel diameter (mm) 3.97671.003 3.59570.766 0.1063
Average vessel diameter (mm) 4.34070.944 3.93270.749 0.0715
Vessel area (mm2) 15.52676.140 12.61474.521 0.0422*
Plaque area (mm2) 12.99575.895 10.13774.457 0.04*
Plaque burden (%) 80.685710.011 77.54279.589 0.2287
Max intima thickness (mm) 1.95170.625 1.61970.482 0.026*
Min intima thickness (mm) 0.59570.355 0.51070.379 0.3914
Average intima thickness (mm) 1.23370.425 1.07870.381 0.15
Remodeling index 1.04070.425 0.84270.277 0.0533
VH-IVUS data
Fibrous area (mm2) 5.82273.266 4.21772.047 0.035*
Fibrous area (%) 58.743710.429 57.004716.610 0.6443
Fibrous fatty area (mm2) 2.52972.539 1.84372.239 0.2791
Fibrous fatty area (%) 21.271715.085 20.352712.647 0.8015
Necrotic core area (mm2) 1.42171.149 1.06470.720 0.1749
Necrotic core area (%) 15.21379.152 14.72477.557 0.8246
Dense calcium area (mm2) 0.51170.681 0.44970.632 0.7237
Dense calcium area (%) 4.76574.504 7.921714.289 0.284
Data is shown as mean7SD. *:The difference between ACS and SCD is statistically signiﬁcant with Po0.05. IVUS, intravascular
ultrasound; Max, maximum; Min, minimum; VH-IVUS, virtual histology-intravascular ultrasound; Remodeling index, calcu-
lated as the ratio of vessel area at the measured lesion (minimum lumen area site) to the reference vessel area (average of the
proximal and distal reference segments).
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Fig. 3. Comparisons of the percentages of the four examined component areas within plaque areas determined by VH-IVUS
between ACS and SCD patients. N.S., not signiﬁcant.
Fig. 4. Correlation between EPA/AA and %Plaque burden. EPA/AA was inversely and signiﬁcantly correlated with %Plaque
burden (R¼0.261, P¼0.048). This ﬁgure is based on the data presented in Table 5.
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Table 3
Univariate logistic regression analysis for acute coronary syndrome.
Variable OR Single variable 95% CI P
Male 1.19 0.383–3.699 0.763
Age475 years:median 0.825 0.300–2.270 0.71
LDL-C:median 1.68 0.405–6.962 0.474
hsCRPZ1350:median 6.984 2.193–22.247 0.001*
AAZ167.5:median 0.825 0.300–2.270 0.71
DHAo137.3:median 6.857 2.207–21.304 0.001*
EPAo60.6:median 14.3 4.083–50.078 o0.001*
DHA/AAo0.79:median 3.231 1.122–9.303 0.030*
EPA/AAo0.37:median 8.4 2.609–27.047 o0.001*
OR, odds ratio. *:The value of OR is statistically signiﬁcant with Po0.05. AA, arachidonic acid; DHA, docosahexaenoic acid; EPA,
eicosapentaenoic acid; hsCRP, high-sensitivity C-reactive protein; LDL-C low-density lipoprotein cholesterol.
Table 4
Multiple logistic regression analysis for acute coronary syndrome.
Model 1 Model 2
Variable OR (95% CI) P OR (95% CI) P
hsCRP≧1350:median 4.456 (1.161–
17.106)
0.029* 5.48 (1.458–
20.595)
0.012*
EPAo60.6:median 8.879 (1.776–
44.395)
0.008*
DHAo137.3:median 1.521 (0.305–
7.596)
0.609
EPA/AAo0.37:median 8.235 (1.436–
47.227)
0.018*
DHA/AAo0.79:
median
0.998 (0.168–
5.950)
0.999
*:The value of OR is statistically signiﬁcant with Po0.05. AA, arachidonic acid; CI, conﬁdence interval; DHA, docosahexaenoic
acid; EPA, eicosapentaenoic acid; hsCRP, high-sensitivity C-reactive protein; OR, odds ratio.
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Data are presented as the mean7standard deviation. Categorical data are presented as number
(n) and percentage (%). Categorical and continuous variables were compared between the ACS and
SCD groups using the chi-square test and Student's unpaired t-test, respectively (Tables 1 and 2,
Figs. 2 and 3). Risk factors of ACS were identiﬁed using univariable and multivariable logistic
regression analysis. All continuous data were categorized because linearity on the logit-scale could
not be achieved with continuous covariables. The factors showing Po0.2 in the univariable test were
entered into a multivariable logistic analysis. Signiﬁcant prognostic factors were selected with a
forward selection strategy using the likelihood ratio statistic (Table 3). In addition, multiple logistic
analyses were performed using two models to avoid multicollinearity (Table 4). All statistical
assessments were two-sided and evaluated at the 0.05 level of signiﬁcance. Correlations of the EPA,
EPA/AA, DHA, and DHA/AA data between the gray-scale and VH-IVUS data are shown in Table 5 and
Figs. 4–7. All statistical analyses were performed using SPSS 19.0 for Windows (SPSS Inc., Chicago, IL).
2.5. Limitations
Two limitations of this data warrant mention. First, the data was obtained at a single center from a
relatively small number of patients. Data from a larger number of patients and multiple centers are
Table 5
Correlation of EPA, EPA/AA, DHA and DHA/AA to gray-scale data and VH-IVUS data.
EPA correlation index P EPA /AA correlation
index
P DHA correlation
index
P DHA/AA correlation
index
P
Gray scale-IVUS data
Max luminal diameter (mm) 0.155 0.247 0.137 0.304 105 0.435 0.047 0.724
Min luminal diameter (mm) 0.143 0.264 0.045 0.737 0.07 0.603 0.158 0.237
Average luminal diameter
(mm)
0.077 0.567 0.041 0.761 0.032 0.814 0.149 0.263
Luminal area (mm2) 0.087 0.47 0.057 0.673 0.009 0.944 0.141 0.293
Max vessel diameter (mm) 0.296 0.024* 0.321 0.014* 0.233 0.079 0.233 0.078
Min vessel diameter (mm) 0.233 0.078 0.253 0.055 0.217 0.102 0.201 0.129
Average vessel diameter (mm) 0.267 0.043* 0.285 0.030* 0.222 0.093 0.209 0.116
Vessel area (mm2) 0.289 0.028* 0.291 0.027* 0.249 0.059 0.213 0.109
Plaque area (mm2) 0.286 0.029* 0.293 0.025* 0.258 0.051 0.235 0.076
Plaque burden (%) 0.185 0.163 0.261 0.048* 0.167 0.212 0.253 0.055
Max intima thickness (mm) 0.309 0.018* 0.342 0.009* 0.255 0.053 0.28 0.033*
Min intima thickness (mm) 0.161 0.23 0.182 0.175 0.215 0.108 0.233 0.082
Average intima thickness
(mm)
0.248 0.06 0.283 0.031* 0.2 0.132 0.236 0.074
Remodeling index 0.157 0.248 0.131 0.341 0.163 0.229 0.083 0.541
VH-IVUS data
Fibrous area (mm2) 0.294 0.025* 0.292 0.026* 0.233 0.078 0.214 0.106
Fibrous area (%) 0.154 0.248 0.264 0.046* 0.007 0.96 0.155 0.245
Fibro fatty area (mm2) 0.241 0.068 0.249 0.06 0.212 0.111 0.179 0.179
Fibro fatty area (%) 0.176 0.186 0.229 0.084 0.134 0.316 0.147 0.271
Necrotic core area (mm2) 0.073 0.584 0.06 0.656 0.161 0.228 0.122 0.362
Necrotic core area (%) 0.107 0.424 0.141 0.292 0.033 0.805 0.005 0.97
Dense calcium area (mm2) 0.121 0.367 0.125 0.35 0.036 0.789 0.026 0.847
Dense calcium (%) 0.334 0.011* 0.513 o0.001* 0.181 0.174 0.375 0.004*
*:The difference between ACS and SCD is statistically signiﬁcant with Po0.05. IVUS, intravascular ultrasound; Max, maximum; Min, minimum.
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Fig. 5. Correlation between EPA/AA and %DC. EPA/AA was signiﬁcantly correlated with %DC (R¼0.513, Po0.01). This ﬁgure is
based on the data presented in Table 5.
Fig. 6. Correlation between EPA and %DC. EPA was signiﬁcantly correlated with %DC (R¼0.334, P¼0.01). This ﬁgure is based on
the data presented in Table 5.
T. Ohwada et al. / Data in Brief 7 (2016) 1237–1247 1245
Fig. 7. Correlation between DHA/AA and %DC. DHA/AA was signiﬁcantly correlated with %DC (R¼0.375, P¼0.004). This ﬁgure
is based on the data presented in Table 5.
T. Ohwada et al. / Data in Brief 7 (2016) 1237–12471246needed to verify the correlations detected here. Second, the relationship between plaque calciﬁcation
and PUFAs could not be determined from the data. Further experimental examination will be needed
to determine the factors underlying this relationship.Competing interests
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